There are no reports of intoxication due to an overdose of the drug. The composition of the drug and the results of the study of its toxicity in animals indicate that an overdose is unlikely.
pregnancy,
breastfeeding period,
children under 12 years of age (for Broncho-munal®, caps. 7 mg),
children under 6 months of age (for Broncho-munal® P, caps. 3,5 mg).
There was no interaction of the drug with other drugs. The drug can be used simultaneously with other drugs, including antibiotics.
Broncho-munal®
Capsules, 7 mg. Light beige powder, placed in solid gelatin capsules of size No. 3, the lid and body are blue opaque.
Broncho-munal® P
Capsules, 3.5 mg. Light beige powder placed in solid gelatin capsules of size No. 3, the lid is blue opaque, the body is white opaque.
The drug is usually well tolerated. Most of the adverse reactions are classified in the general category with a moderate or moderate-severe degree of manifestation. The most common manifestation of side effects is gastrointestinal disorders, skin reactions and respiratory disorders.
Adverse effects are listed according to the WHO classification by frequency as follows: very common (≥1/10), common (≥1/100, <1/10), infrequent (≥1/1000, <1/100), rare (≥1/10000, <1/1000), very rare (<1/10000), frequency unknown (frequency of occurrence cannot be determined based on available data).
From the gastrointestinal tract: often-diarrhea, abdominal pain, frequency unknown-nausea, vomiting.
From the respiratory system: often-cough, infrequently-shortness of breath.
From the skin and subcutaneous tissues: often-rash, the frequency is unknown-urticaria, angioedema.
From the immune system: infrequently-hypersensitivity reactions (erythematous rash, generalized rash, erythema, edema, including eyelids, faces, peripheral edema, swelling, including faces, itching, including generalized).
From the nervous system: frequency unknown-headache.
General disorders: the frequency is unknown-fever, fatigue.
Without a prescription.
Possible manifestations of hypersensitivity reactions to the drug. In case of persistent gastrointestinal disorders, skin reactions, respiratory disorders or other symptoms of intolerance, you should cancel the drug and consult a doctor.
Influence on the ability to drive vehicles, work with mechanisms. The drug does not affect the ability to concentrate and drive vehicles, mechanisms.
Broncho-munal® P
To avoid overdose, children from 6 months to 12 years should not use Broncho-Munal®, caps. 7 mg, intended for adults.
as part of the complex therapy of acute respiratory tract infections,
prevention of recurrent respiratory tract infections and exacerbations of chronic bronchitis.
The drug has an immunostimulating effect, strengthening immunity against respiratory tract infections.
After taking the capsule, bacterial lysate accumulates in the Peyer plaques of the gastrointestinal mucosa, in particular those located in the small intestine. Antigen-presenting cells in Peyer's plaques are activated by bacterial lysate and subsequently stimulate other cell types (B-lymphocytes) responsible for specific immunity. This leads to an increase in the number of circulating B-lymphocytes, which leads to an increase in the production of polyclonal antibodies, especially serum IgG and IgA, secreted by the respiratory mucosa and salivary glands. The drug also stimulates the majority of white blood cells, which is characterized by an increase in the number of cells of the myeloid and lymphoid series, as well as a selective increase in the expression of receptors on the surface
In patients receiving the drug, the body's protective properties against bacteria and viruses are enhanced.
Clinically, the drug reduces the frequency of acute respiratory tract infections, reduces the duration of their course, reduces the likelihood of exacerbations of chronic bronchitis, and also increases the body's resistance to infections of the respiratory system. At the same time, the need for the use of other drugs, especially antibiotics, is reduced.
At a temperature of 15-25 °C.
Keep out of reach of children.
Shelf life of the drug Broncho-munal® P5 лет.Do not use after the expiration date indicated on the package.
Broncho-munal®
| Capsules | 1 caps. |
| active ingredients: | |
| standardized lyophilizate of bacterial lysates (OM-85) - 40 mg (including lyophilized bacterial lysates Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus viridans, Streptococcus pyogenes, Klebsiella pneumoniae, Klebsiella ozaenae, Staphylococcus aureus, Moraxella catarrhalis — 7 mg), propyl gallate (anhydrous) - 0.084 mg, sodium glutamate (anhydrous) - 3.03 mg, mannitol-up to 40 mg | |
| excipients: magnesium stearate-3 mg, pre-gelatinized starch-110 mg, mannitol-up to 200 mg | |
| capsule shell: Indigotin (E132) - 0.03 mg, titanium dioxide (E171) - 0.98 mg, gelatin-up to 50 mg |
Broncho-munal® P
| Capsules | 1 caps. |
| active ingredients: | |
| standardized lyophilizate of bacterial lysates (OM-85) - 20 mg (including lyophilized bacterial lysates Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus viridans, Streptococcus pyogenes, Klebsiella pneumoniae, Klebsiella ozaenae, Staphylococcus aureus, Moraxella catarrhalis - 3.5 mg), sodium glutamate (anhydrous) - 1,515 mg, propyl gallate (anhydrous) - 0.042 mg, mannitol-up to 20 mg | |
| excipients: magnesium stearate-3 mg, pre-gelatinized starch-110 mg, mannitol-up to 200 mg | |
| capsule shell: Indigotin (E132) - 0.009 mg, titanium dioxide (E171) - 0.98 mg, gelatin-up to 50 mg |
Broncho-munal®, capsules, 7 mg. 10 caps each in a blister. 1 or 3 bl. in a cardboard pack.
Broncho-munal® P, capsules, 3.5 mg. 10 caps each in a blister. 1 or 3 bl. in a cardboard pack.
Animal studies have not revealed a negative effect on the course of pregnancy. The safety and efficacy of the drug during pregnancy and during breastfeeding has not been studied, so the use of the drug during pregnancy and during breastfeeding is contraindicated.
Broncho-munal®
Inside, 1 capsule a day in the morning, on an empty stomach, 30 minutes before meals.
To prevent recurrent respiratory tract infections and exacerbations of chronic bronchitis, the drug is used in three courses of 10 days, the interval between courses is 20 days.
As part of the complex therapy of acute respiratory tract infections, the drug is used until the symptoms disappear, but not less than 10 days. When conducting antibiotic therapy with Broncho-munal® it should be taken in combination with antibiotics from the beginning of treatment. The next 2 months may be preventive use of the drug in courses of 10 days, the interval between courses of 20 days.
If the capsule is difficult to swallow, it should be opened, the contents mixed with a small amount of liquid (for example, tea, milk or juice).
Broncho-munal® P
Inside, 1 capsule a day in the morning, on an empty stomach, 30 minutes before meals.
Children under 3 years of age or if the child has difficulty swallowing the capsule, it should be opened, the contents mixed with a small amount of liquid (tea, milk or juice).
To prevent recurrent respiratory tract infections and exacerbations of chronic bronchitis, the drug is used in three courses of 10 days, the interval between courses is 20 days.
As part of the complex therapy of acute respiratory tract infections, the drug is used until the symptoms disappear, but not less than 10 days. When conducting antibiotic therapy with Broncho-munal® P should be taken in combination with antibiotics from the beginning of treatment.
The next 2 months, preventive use of the drug is possible in courses of 10 days, the interval between courses is 20 days.
L03AX Other Immunostimulants
